Sonenshine Partners Advises Naviscan PET Systems on a Capital Raise from Sanderling Ventures and Mayo Medical Ventures
Company Press Release
September 14, 2005

New York, N.Y. – Sonenshine Partners today announced that it has advised Naviscan PET Systems, Inc. on a private financing from Sanderling Ventures and Mayo Medical Ventures, two leading venture capital firms.

Founded in 1995 and headquartered in Rockville, MD, Naviscan PET Systems, Inc. has developed a patented, organ specific, positron emission tomography (PET) technology platform with broad applications in the diagnosis of breast cancer and other diseases. The Company has FDA clearance to market its capital PEM FlexTM device for high-resolution PET.

Founded in 1979, Sanderling is among the oldest investment firms specializing in seed/start-up and early-stage financings in the areas of biotechnology, therapeutics, pharmaceuticals, drug delivery, medical devices and instrumentation, imaging and diagnostics, medical informatics and health care services.

Mayo Medical Ventures (MMV) is a division of Mayo Foundation for Medical Education and Research. MMV was started in 1986 as a response to ever-tightening reimbursement for patient care services. MMV's charge is to generate new sources of revenue to support Mayo's clinical practice, medical education and medical research activities.

Sonenshine Partners is a leading independent investment bank focused on providing integrated strategic, financial and corporate advisory services.  The firm was founded in 2000 and is headquartered in New York City.